Michael B Levy
Overview
Explore the profile of Michael B Levy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
367
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Elizur A, Appel M, Nachshon L, Levy M, Epstein-Rigbi N, Koren Y, et al.
Allergy
. 2022 Jan;
77(6):1863-1872.
PMID: 35000223
Background: Oral immunotherapy (OIT) is a treatment option for patients with milk, egg, and peanut allergy, but data on the efficacy and safety of cashew OIT are limited. Methods: A...
12.
Nachshon L, Levy M, Goldberg M, Epstein-Rigbi N, Schwartz N, Katz Y, et al.
J Allergy Clin Immunol Pract
. 2022 Jan;
10(4):1070-1076.e2.
PMID: 34982978
Background: Home reactions requiring epinephrine treatment represent a significant obstacle to oral immunotherapy (OIT) and impair treatment outcome. Objective: To identify potential triggers for such reactions for improvement of patient...
13.
Nachshon L, Goldberg M, Levy M, Epstein-Rigbi N, Koren Y, Elizur A
Ann Allergy Asthma Immunol
. 2021 May;
127(4):451-455.e1.
PMID: 34010698
Background: Oral immunotherapy (OIT) is effective in desensitizing patients with food allergy but adverse reactions limit its use. Objective: To study the effect of the coronavirus disease 2019 lockdown in...
14.
Goldberg M, Appel M, Nachshon L, Holmqvist M, Epstein-Rigbi N, Levy M, et al.
Pediatr Allergy Immunol
. 2021 May;
32(7):1482-1489.
PMID: 33955090
Background: The prevalence of sesame food allergy (SFA) is increasing worldwide with the potential of anaphylactic reactions upon exposure. Utility of specific component IgE testing as an alternative to the...
15.
Epstein Rigbi N, Schwartz N, Goldberg M, Levy M, Nachshon L, Elizur A
Pediatr Allergy Immunol
. 2021 Jan;
32(5):1029-1037.
PMID: 33452829
Background: The start of oral immunotherapy (OIT) for food allergy is a critical period in the treatment process, with a potential to influence patient quality of life (QOL) and subsequently...
16.
Nachshon L, Zipper O, Levy M, Goldberg M, Epstein-Rigby N, Elizur A
Pediatr Allergy Immunol
. 2020 Oct;
32(2):342-348.
PMID: 33040398
Background: Subjective oral symptoms, especially if recurrent, might lead to termination of an oral food challenge (OFC) for fear of a subsequent severe reaction. Methods: In a single-center retrospective cohort...
17.
Goldberg M, Appel M, Nega R, Levy M, Epstein-Rigbi N, Nachshon L, et al.
J Allergy Clin Immunol Pract
. 2020 Oct;
9(1):265-274.e6.
PMID: 33039644
Background: We previously devised an algorithm using skin prick tests (SPT), basophil activation tests (BAT), and co-allergy status to reduce the need for oral food challenges (OFCs) in 63 patients...
18.
Nachshon L, Schwartz N, Tsviban L, Levy M, Goldberg M, Epstein-Rigby N, et al.
J Allergy Clin Immunol Pract
. 2020 Aug;
9(1):185-192.e3.
PMID: 32750430
Background: Oral immunotherapy (OIT) is effective in desensitizing food-allergic patients but adverse events limit its applicability. Objective: To identify risk factors for home epinephrine-treated reactions during the build-up phase of...
19.
Epstein-Rigbi N, Goldberg M, Levy M, Nachshon L, Elizur A
Allergy
. 2020 May;
75(10):2623-2632.
PMID: 32350869
Background: Oral immunotherapy (OIT) for food allergy improves the quality of life (QOL) of children from parental perspective but little is known about the child perception. Methods: The Food Allergy...
20.
Elizur A, Nachshon L, Levy M, Epstein-Rigbi N, Goldberg M
J Allergy Clin Immunol
. 2020 Apr;
145(5):1480-1481.
PMID: 32223980
No abstract available.